Publications

Oncologie

Labropoulou V et al. Sustained belinostat-induced metabolic response and tolerability in heavily pretreated relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report. Clinical Case Reports 2026. Epub ahead a print (aide à la rédaction)

Niedersuess-Beke D et al. Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: an Austrian real-world analysis. Int J Cancer 2025; 158(6):1654-1665. DOI: 10.1002/ijc.70203 (aide à la rédaction)

Faiman B et al. A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments. Front Oncol 2025; 15:1628121. DOI: 10.3389/fonc.2025.1628121 (aide à la rédaction)

Even C et al. Randomized Clinical efficacy and safety trial of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. J Immunother Cancer 2025; 13(9):e012555. DOI: 10.1136/jitc-2025-012555 (aide à la rédaction)

Boulmé F. EHA congress report 2025, memo InHaematology Springer-Verlag GmbH

Pichler R et al. Local therapy of the primary tumor: an option for metastatic urothelial carcinoma in the era of novel combination therapies? Eur Urol Open Sci 2025; 78:69-71. DOI: 10.1016/j.euros.2025.05.016 (aide à la rédaction)

Boulmé F. Rapport de congrès EBMT 2025, memo InHaematology Springer-Verlag GmbH

Niedersuess-Beke et al. Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study. Clin Genitourinary Cancer 2025; 23(1):10227. DOI: 10.1016/j.clgc.2024.102278 (auteur)

Frank P et al. Experience and care pathway of patients with lung cancer: an online international survey. Oncol & Ther 2024; 13(1):145-164. DOI: 10.1007/s40487-024-00314-2 (aide à la rédaction)

Santagostino A et al. Challenging management of relapsed/refractory angioimmunoblastic T-cell lymphoma: insights from two complex cases with long-term response to belinostat. Ann Case Reports 2024; 9(6):2059. DOI:10.29011/2574-7754.102059 (aide à la rédaction)

Boulmé F. Rapport de congrès EBMT 2024, memo InHaematology Springer-Verlag GmbH

Wilde S et Graux C. Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: a case report. Clin Case Report 2024; 12(7):e9159. DOI: 10.1002/ccr3.9159 (aide à la rédaction)

Boulmé F. Rapport de congrès sur les tumeurs solides SABCS 2023, special memo InOncology/PharmaNews Springer-Verlag GmbH

Boulmé F. Rapport de congrès sur les tumeurs solides EANM 2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/4b2LNKh)

Camus V et al. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report. Clin Case Report 2023; 11(6):e7623. DOI: 10.1002/ccr3.7623 (aide à la rédaction)

Filipits M et al. Epidermal growth factor receptor T790M mutation testing in non-small cell lung cancer: an international collaborative study to assess molecular EGFR T790M testing in liquid biopsy. Cancers 2023; 15(13):3528. DOI: 10.3390/cancers15133528 (aide à la rédaction)

Illini O et al. Characteristics and treatment outcomes in advanced-stage non-small cell lung cancer patients with a KRAS G12C mutation: a real-world study. J Clin Med 2022; 11(14):4098. DOI: 10.3390/jcm11144098 (aide à la rédaction)

Illini O et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol 2022;14:17588359221103206. DOI: 10.1177/17588359221103206 (aide à la rédaction)

Joly F, Lefevre L, Stitou H, Bombezin–Domino A. Patient perspectives on the daily burden of prostate cancer: an online patient study. JMIR 2022; epub ahead a print. DOI: 10.2196/preprints.42973 (aide à la rédaction)

Boulmé F. Rapport de congrès sur les tumeurs solides ASCO 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3fKeGRg)

Boulmé F. Rapport de congrès sur les tumeurs solides ESMO 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3IJhdYv)

Boulmé F. Rapport de congrès sur les tumeurs solides ESMO-IO 2021/2022, memo InOncology Springer-Verlag GmbH (bit.ly/3IJhdYv)

Boulmé F. Rapport de congrès ASH 2020/2022, memo InHaematology Springer-Verlag GmbH

Boulmé F. Rapport de congrès iwWM 2022, memo InHaematology Springer-Verlag GmbH

Hochmair MJ et al. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report. Clin Lung Cancer 2021; S1525-7304(21)00277-1. DOI: 10.1016/j.cllc.2021.11.002 (aide à la rédaction)

Illini O et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol 2021; 13:17588359211019675. DOI: 10.1177/17588359211019675 (aide à la rédaction)

Boulmé F. RET comme cible thérapeutique dans les cancers du poumon et de la thyroide. SPECTRUM Onkologie e-news. Medahead, Juin 2021, en allemand (bit.ly/3w4txf0)

Boulmé F. RET comme driver oncogénique dans le cancer avancé de la thyroide. SPECTRUM Onkologie e-news. Medahead, Juin 2021, en allemand (bit.ly/3x7m5kq)

Boulmé F. FMC: La maladie des cellules falciformes. Die Punkte:On, MedMedia Austria, Mai 2021, en allemand

Boulmé F. Selpercatinib chez des patients atteints d’un stage avancé de cancer du poumon (NSCLC) avec une fusion positive à RET. Rapport de cas (en allemand) MedMedia, Mars 2021 (bit.ly/3VYSB75)

Boulmé F. FMC: La nouvelle ère de l’immunothérapie dans le cancer: le rôle du médecin de famille. Die Punkte:On, Medizin Medien Austria, Mars 2021, en allemand (bit.ly/49XSmi9)

Hochmair MJ et al. Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anticancer Drugs 2021; 32(1): 105-110. DOI: 10.1016/j.cllc.2021.11.002 (aide à la rédaction)

Boulmé F. FMC: “Real World Evidence”. CliniCum Onko, Medizin Medien Austria, septembre 2020, en allemand (bit.ly/4a1w2o8)

Boulmé F. Prise de position: avons-nous besoin de changer la thérapie du RCC pendant l’épidemie de COVID-19? Meeting d’experts virtuel, RCC Academy, aout 2020, en allemand (bit.ly/3W2rGqL)

Boulmé F. medonline: Onko News (articles en allemand), 2020 (bit.ly/3PgcVNh)

Boulmé F. FMC: Oncologie de précision. CliniCum Onko, Medizin Medien Austria, avril 2020, en allemand (bit.ly/3BSmbnR)

Boulmé F. Cancer du poumon; première cause de décès. Ärzte Woche (9), Springer-Verlag, février 2020, en allemand

Virologie

Custovic A et al. Multi-country cross-sectional survey on parents’ perception of RSV disease and subsequent wheezing burden. Pediatric allergy and immunology 2024; 35(6):e14169. DOI: 10.1111/pai.14169 (aide à la rédaction)

Boulmé F. Rapport de congrès ECCMID 2023

Bouwensch C et al. Analysis of 160 nonhospitalized COVID-19 patients with mild to moderate symptoms from an Austrian general medical practice: from typical disease pattern to unexpected clinical features. Wiener Medizinische Wochenschrift 2022; 172(9-10):198-210. DOI: 10.1007/s10354-022-00919-0 (auteur)

LaMori J et al. Patient satisfaction with once-daily single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (DRV/c/FTC/TAF): a real-world study of patient self-reported outcomes in HIV-1-diagnosed adults.Patient Prefer Adherence 2022; 16:83-94. DOI: 10.2147/PPA.S332555 (aide à la rédaction)

Blakemore C et al. Rapid swallow improvement following pharyngeal electrical stimulation in a COVID-19 patient with long-term severe neurogenic dysphagia: a case report. JRM-CC 2021; 4:1000073. DOI: 10.2340/20030711-1000073 (aide à la rédaction)

Pécout C et al. Impact of the COVID-19 pandemic on patients affected by non-communicable diseases in Europe and in the USA. Int J Environ Res Public Health 2021;18(13):6697. DOI: 10.3390/ijerph18136697 (aide à la rédaction)

M. Traugott et al. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2020; 15(1):148. DOI: 10.1186/s13256-021-02763-z (aide à la rédaction)

Boulmé F. Recommandations pour le traitement en unité de soins intensifs des patients positifs au SARS-CoV-2. Ärzte Woche (17), Springer-Verlag, avril 2020, en allemand

Boulmé F. FMC: SARS-CoV-2 dans la salle d’attente. Ärzte Woche (12), Springer-Verlag, mars 2020, en allemand (bit.ly/3ZW9xfA)

Freund F et al. Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex. Nucleic Acids Res 2001; 29:2757-2765. DOI: 10.1093/nar/29.13.2757 (auteur)

Freund F et al. Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex. Antisense Nucleic Acid Drug Dev 2001; 11:301-315 DOI: 10.1089/108729001753231687 (auteur)

Litvak S et al. (2001) Reverse transcriptase of HIV-1: novel therapeutic interventions” in “Pharmacology of HIV infection and AIDS, edited by Dietmar Fuchs, OICA International Press, Saint-Lucia, London (auteur)

Boulmé F et al. Study of HIV-2 primer-template initiation complex using antisense oligonucleotides. Eur J Biochem 2000; 267:2803-2811. DOI: 10.1046/j.1432-1327.2000.01310.x

Mestre B et al. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999; 1445:86-98. DOI: 10.1016/s0167-4781(99)00019-6 (auteur)

Boulmé F. In vitro effect of phosphodiester and chemically modified antisense oligonucleotides on the initiation step of the HIV-1 and HIV-2 reverse transcription. PhD obtained on the 22nd of June1998, University of Bordeaux II, France.

Boulmé F et al. Modified (PNA, 2’O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res 1998; 26:5492-5500. DOI: 10.1093/nar/26.23.5492

Boulmé F et al. Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 and HIV-2 RNAs by both type 1 and type 2 reverse transcriptases. FEBS Letters 1998; 430:165-170. DOI: 10.1016/s0014-5793(98)00649-8

Dufour E et al. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: interactions with primer tRNALys3, initiation of cDNA synthesis and effect of inhibitors. Eur J Biochem 1998; 251:487-495. DOI: 10.1046/j.1432-1327.1998.2510487.x (auteur)

Boulmé F et al. Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochim Biophys Acta 1997; 1351:249-255. DOI: 10.1016/s0167-4781(97)00026-2

Dermatologie

Rapport sur la conférence annuelle ÖGDV, Société autrichienne de dermatologie et vénérologie, SKIN International, Novembre 2025 (en allemand)

Rapport sur la conférence annuelle ÖADF, Société autrichienne de dermatologie et vénérologie, SKIN International, Mai 2024 (bit.ly/4iWYNpQ) (en allemand)

Mateeva V et al. Patient with severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36 monoclonal antibody. J German Soc Derm 2024; 84(1):45-58. DOI: 10.1111/ddg.15334 (aide à la rédaction)

Rapport sur la conférence annuelle ÖGDV, Société autrichienne de dermatologie et vénérologie, SKIN International, Nov 2023 (bit.ly/4a3qZDB) (en allemand)

Preibisz L et al. Barbed polydioxanone sutures for face recountouring: six-month safety and effectiveness data supported by objective markerless tracking analysis. Aesthet Surg J 2022; 42(1):NP41-NP54. DOI: 10.1093/asj/sjab359 (auteur)

Neurologie

Lucas C et al. Migraine management in France: practices of general practitioners and neurologists. Rev Neurol 2025; S0035-3787(25)00546-6. DOI: 10.1016/j.neurol.2025.06.006 (aide à la rédaction)

Muhle P et al. Pharyngeal electrical stimulation prior to extubation – Reduction of extubation failure rate in acute stroke patients? J Crit Care 2024; 82:154808, 82:154808. DOI: 10.1016/j.jcrc.2024.154808 (aide à la rédaction)

Likar R et al. Management of swallowing disorders in ICU patients – a multinational expert opinion. J Crit Care 2024; 79:154447. DOI: 10.1016/j.jcrc.2023.154447 (aide à la rédaction)

Traugott MT et al. Pharyngeal electrical stimulation treatment of critically Ill intensive care tracheostomized patients presenting with severe neurogenic dysphagia: a case series. Austin J Pulm Respir Med 2022; 9(1):1088 DOI: 10.26420/austinjpulmrespirmed.2022.1088 (aide à la rédaction)

Traugott MT et al. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2021; 15(1):148. DOI: 10.1186/s13256-021-02763-z (aide à la rédaction)

Beirer S et al. Therapy-resistant dysphagia successfully treated using pharyngeal electrical stimulation in a patient with the pharyngeal-cervical-brachial variant of the Guillain-Barré syndrome. eNeurologicalSci 2020; 20:100255. DOI: 10.1016/j.ensci.2020.100255 (aide à la rédaction)

Rhumatologie

Roux C et al. Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database. Joint Bone Spine 2022; 89(4): 105340. DOI: 10.1016/j.jbspin.2021.105340 (aide à la rédaction)

Diabète

Jeandidier N et al. Tubeless insulin pump combined with a cloud-based data management platform: Real-world evidence from 14,765 French people with diabetes. Diabetes Tech & Ther 2025; epub ahead a print. DOI: 10.1007/s13300-025-01814-8 (aide à la rédaction)

Cerletti P et al. Evaluating digital health solutions in diabetes and the role of patient-reported outcomes: targeted literature review. JMIR Diabetes 2025;10:e52909. DOI: 10.2196/52909 (aide à la rédaction)

Skovlund SE et al. Identification of core outcome domains and design of a survey questionnaire to evaluate impacts of digital health solutions that matter to people with diabetes. J Diabetes Sci Technol 2025; 19(1):136-142. DOI : 10.1177/19322968231179740 (aide à la rédaction)

Hématologie/Hémato-oncologie

Labropoulou V et al. Sustained belinostat-induced metabolic response and tolerability in heavily pretreated relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report. Clinical Case Reports 2026. Epub ahead a print (aide à la rédaction)

Boulmé F. Rapport de congrès EBMT 2024, special memo InOncology, Springer-Verlag GmbH

Boulmé F. Traitement précoce de la polycythémie véra, même en cas de risque faible. Rapport de congrès ÖHEM 2022. memo InHaematology special issue by Springer-Verlag GmbH.

Boulmé F. Néoplasmes myéloprolifératifs/polycythémie de Vera : perspectives de la thérapie moderne à l’interféron. Rapport de congrès e-IHEM 2021. memo InHaematology special issue by Springer-Verlag GmbH.

Boulmé F. Diagnostique de la mastocytose, meeting d’experts, Mai 2021.

Boulmé F. FMC: La maladie des cellules falciformes. Die Punkte:On, MedMedia Austria, Mai 2021.

Boulmé F. FMC: Diagnostique de la mastocytose systémique. Die Punkte:On, Medmedia Austria, Avril 2021, en allemand (bit.ly/40eHp8K)

Pradet-Balade B et al. Massive translational repression of gene expression during mouse erythroid differentiation. Biochim Biophys Acta 2010; 1799:630-641. DOI: 10.1016/j.bbagrm.2010.08.006 (auteur)

Leberbauer C et al. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 2005; 105:85-94. DOI: 10.1182/blood-2004-03-1002 (auteur)

Joosten M et al. Translational control of putative proto-oncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling. J Biol Chem 2004; 279:38169-38176. DOI: 10.1074/jbc.M401283200 (auteur)

Dolznig H et al. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J 2001;15,:442-1444. DOI: 10.1096/fj.00-0705fje (auteur)

Asthme

Bridevaux PO et al. Substantial reduction in oral corticosteroid use after biologics initiation in severe asthma: an analysis based on Swiss pharmacy data. Respiratory Med 2025; 248:108312. DOI: 10.1016/j.rmed.2025.108312 (aide à la rédaction)

George M et al. Patients with severe uncontrolled asthma: perception of asthma control and its management. Pulm Ther 2022; 8(2): 209-222. DOI: 10.1007/s41030-022-00190-z (aide à la rédaction)

Réhabilitation

Spielmanns M et al. Impact of malnutrition and sarcopenia on the outcomes of pulmonary rehabilitation in patients with COPD (en allemand). Pneumologie 2025; epub ehead a print. DOI: 10.1055/a-2677-8679 (aide à la rédaction)

P Alter et al. The Montafon proposal: New insights and emerging concepts in pulmonary rehabilitation. Respiration 2026. Epub ahead a print (auteur)

Contrôle de la traduction

Pradet-Balade B, Boulmé F, Beug H, Müllner, EW et al. Translation control: bridging the gap between genomics and proteomics?. Trends Biochem Sci 2001; 26:225-229. DOI: 10.1016/s0968-0004(00)01776-x (auteur)

Pradet-Balade B, Boulmé F, Müllner, EW, Garcia-Sanz JA. Reliability of mRNA profiling: verification for samples with different complexities. Biotechniques 2001; 30:1352-1357. DOI: 10.2144/01306rr03 (auteur)